Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Ultratech Announces Fourth Quarter and Year End 2006 Results

Abstract:
Ultratech, Inc. (NasdaqGM: UTEK), today announced unaudited results for the three-month and one year periods ended December 31, 2006.

Ultratech Announces Fourth Quarter and Year End 2006 Results

SAN JOSE, CA | Posted on February 1st, 2007

For the fourth quarter of fiscal 2006, Ultratech reported net sales of $24.7 million, as compared to $35.2 million during the fourth quarter of fiscal 2005. Ultratech's net loss for the fourth quarter of 2006 was $6.8 million, or $0.29 per share, as compared to net income, before the cumulative effect of a change in accounting principle, of $2.5 million, or $0.10 per share (diluted), for the same quarter last year. Including the cumulative effect of the change in accounting principle for the adoption of FIN No. 47, "Accounting for Conditional Asset Retirement Obligations," net income for the fourth quarter of 2005 was $1.4 million, or $0.06 per share (diluted).

Ultratech's net sales for the year ended December 31, 2006 were $119.6 million, as compared to $122.4 million for fiscal 2005. Ultratech posted a net loss for the year ended December 31, 2006 of $9.0 million, or $0.38 per share, as compared with a net loss, before the cumulative effect of a change in accounting principle, of $1.2 million or $0.05 per share in fiscal 2005. Including the cumulative effect of the adoption of FIN No. 47, the net loss for the year ended fiscal 2005 was $2.3 million, or $0.10 per share.

Arthur W. Zafiropoulo, President and Chief Executive Officer stated, "During the fourth quarter, the company reassessed the business environment and took necessary cost-cutting steps in the face of continued weakness in our served markets. We have reduced our headcount by approximately 10% and closed non-strategic sales and service locations which will result in lower overall fixed costs. The weakness in our served markets and these initiatives impacted the fourth quarter results and had a negative impact on cash flow."

"Overall in 2006, Ultratech achieved milestones in the laser processing area with 16 of the top 17 logic manufacturers engaged with our LSA products for 65nm production and 45nm development," Zafiropoulo continued. "In the advanced packaging area, we won a significant contract from a major integrated device manufacturer (IDM) for its 45nm and 32nm bump packaging requirements with shipments beginning during the second half of 2007. We continue to maintain our large market share in this area, by offering high economic value and operational flexibility to our customers."

"Entering 2007, Ultratech remains focused on driving improvement in performance through both continued cost discipline and operational management, while at the same time providing our strategic customers with market leading solutions that offer advantages in both technology and cost-efficiency in our served markets," concluded Zafiropoulo.

At December 31, 2006, Ultratech had $126 million in cash, cash equivalents, short-term investments and long-term investments. Working capital was $105 million and stockholders' equity was $7.51 per share based on 23,218,722 total shares outstanding on December 31, 2006.

Conference Call Information

The conference call will be broadcast live over the Internet beginning at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time on Thursday, February 1, 2007. To listen to the call over the Internet or to obtain telephone dial-in information for the call, please go to Ultratech's web site at http://www.ultratech.com . If you are unable to attend the live conference call, a replay will be available on Ultratech's web site. If you do not have Internet access, a replay of the call will be available three hours after the conclusion of the call and run until 9:00 p.m. Pacific Time, February 3, 2007. You may access the telephone replay by dialing 1-888-203-1112 for domestic callers, 1-719-457-0820 for international callers and entering access code: 6463355

- Tables to Follow-

ULTRATECH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
Dec. 31, Dec. 31,
(In thousands ) 2006

2005(a)

ASSETS (Unaudited)
Current assets:
Cash, cash equivalents, and
short-term investments $78,090 $141,067
Accounts receivable 18,054 19,110
Inventories 40,988 28,969
Prepaid expenses and other
current assets 2,181 1,589
Total current assets 139,313 190,735
Long-term investments 48,328 -
Equipment and leasehold
improvements, net 20,368 25,117
Demonstration inventories 4,717 3,367
Other assets 3,324 3,090
Total assets $216,050 $222,309
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Notes payable $6,974 $4,289
Accounts payable 10,440 8,403
Deferred product and service income 2,950 1,970
Other current liabilities 13,998 10,892
Total current liabilities 34,362 25,554
Other liabilities 7,380 7,805
Stockholders' equity 174,308 188,950
Total liabilities and stockholders' equity $216,050 $222,309

(a) The balance sheet as of December 31, 2005 has been derived from the audited financial statements as of that date.

ULTRATECH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
Three Months Ended Year Ended
Dec. 31, Dec. 31, Dec. 31, Dec. 31,
(In thousands, except per share amounts) 2006 2005 2006 2005

Total net sales (a)

$24,703 $35,229 $119,633 $122,366
Cost of sales:
Cost of products sold 14,606 17,420 64,256 60,647
Cost of services 1,991 2,743 9,353 9,672
Total cost of sales 16,597 20,163 73,609 70,319
Gross profit 8,106 15,066 46,024 52,047
Operating expenses:

Research, development, and engineering

6,557 6,671 26,206 26,963
Amortization of intangible assets - - - 95

Selling, general, and administrative

9,675 6,861 34,189 29,864
Operating income (loss) (8,126) 1,534 (14,371) (4,875)
Interest expense (98) (73) (237) (380)
Interest and other income, net 1,820 1,306 6,594 4,733

Income (loss) before tax and cumulative effect of change in accounting principle

(6,404) 2,767 (8,014) (522)
Income taxes 402 293 954 699

Net income (loss) before cumulative effect of change in accounting principle

(6,806) 2,474 (8,968) (1,221)

Cumulative effect of the adoption of FIN47 "Accounting for Conditional Asset Retirement Obligations"

- (1,122) - (1,122)
Net income (loss) ($6,806) $1,352 ($8,968) ($2,343)
Earnings per share - basic:

Net income (loss) before cumulative effect of change in accounting principle

($0.29) $0.10 ($0.38) ($0.05)

Cumulative effect of the adoption of FIN47 "Accounting for Conditional Asset Retirement Obligations"

$0.00 $0.04 $0.00 ($0.05)
Net income (loss) ($0.29) $0.06 ($0.38) ($0.10)
Number of shares used in per share calculations - basic 23,213 23,905 23,764 23,964
Earnings per share - diluted:

Net income (loss) before cumulative effect of change in accounting principle

($0.29) $0.10 ($0.38) ($0.05)

Cumulative effect of the adoption of FIN47 "Accounting for Conditional Asset Retirement Obligations"

$0.00 $0.04 $0.00 ($0.05)
Net income (loss) ($0.29) $0.06 ($0.38) ($0.10)
Number of shares used in per share calculations - diluted 23,213 24,323 23,764 23,964

(a)Systems Sales

$17,322 $28,205 $87,890 $93,233
Parts Sales 4,167 3,956 17,387 15,144
Service Sales 3,214 2,968 14,156 12,472
License Sales - 100 200 1,517
Total Sales $24,703 $35,229 $119,633 $122,366

####

About Ultratech
Ultratech, Inc. (NasdaqGM:UTEK) designs, manufactures and markets photolithography equipment used worldwide in the fabrication of semiconductor and nanotechnology devices, and has expanded its technology scope in pioneering laser processing technology for IC manufacturing. Founded in 1979, Ultratech is a market leader in gold and solder bump lithography. Its products are designed to substantially reduce the cost of ownership for manufacturers in the electronics industry. The company’s home page on the World Wide Web is located at http://www.ultratech.com.

Certain of the statements contained herein, which are not historical facts and which can generally be identified by words such as “anticipates,” “expects,” “intends,” “will,” “could,” “believes,” “estimates,” “continue,” and similar expressions, are forward-looking statements under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties, such as risks related to integration of Oraxion’s technology and products with our technology and products and market acceptance thereof; our dependence on new product introductions and market acceptance of new products and enhanced versions of our existing products; lengthy sales cycles, including the timing of system installations and acceptances; lengthy and costly development cycles for laser-processing and lithography technologies and applications; integration, development and associated expenses of the laser processing operation; delays, deferrals and cancellations of orders by customers; cyclicality in the semiconductor and nanotechnology industries; pricing pressures and product discounts; high degree of industry competition; intellectual property matters; expiration of licensing arrangements, and the resulting adverse impact on our licensing revenues; changes to financial accounting standards; changes in pricing by us, our competitors or suppliers; customer concentration; international sales; timing of new product announcements and releases by us or our competitors; ability to volume produce systems and meet customer requirements; sole or limited sources of supply; ability and resulting costs to attract or retain sufficient personnel to achieve our targets for a particular period; dilutive effect of employee stock option grants on net income per share, which is largely dependent upon us achieving and maintaining profitability and the market price of our stock; mix of products sold; rapid technological change and the importance of timely product introductions; outcome of litigation; changes in accounting policies or interpretations of such policies; manufacturing variances and production levels; timing and degree of success of technologies licensed to outside parties; product concentration and lack of product revenue diversification; inventory obsolescence; asset impairment; effects of certain anti-takeover provisions; future acquisitions; volatility of stock price; foreign government regulations and restrictions and the exporting of sensitive technologies and jobs to certain countries; business interruptions due to natural disasters or utility failures; environmental regulations; and any adverse effects of terrorist attacks in the United States or elsewhere, or government responses thereto, or military actions in Iraq, Afghanistan and elsewhere, on the economy, in general, or on our business in particular. Such risks and uncertainties are described in Ultratech’s SEC reports including its Annual Report on Form 10-K filed for the year ended December 31, 2005, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2006. Due to these and additional factors, the statements, historical results and percentage relationships set forth herein are not necessarily indicative of the results of operations for any future period. These forward-looking statements are based on management’s current beliefs and expectations, some or all of which may prove to be inaccurate, and which may change. We undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

For more information, please click here

Contacts:
Ultratech, Inc.
Bruce Wright, 408-321-8835
Sr. Vice President, Finance/CFO
or
Laura Rebouche, 408-321-8835
Vice President of Investor Relations and
Corporate Communications
UTEK-F

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

Tools

New material to make next generation of electronics faster and more efficient With the increase of new technology and artificial intelligence, the demand for efficient and powerful semiconductors continues to grow November 8th, 2024

Turning up the signal November 8th, 2024

Quantum researchers cause controlled ‘wobble’ in the nucleus of a single atom September 13th, 2024

Faster than one pixel at a time – new imaging method for neutral atomic beam microscopes developed by Swansea researchers August 16th, 2024

Financial Reports

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project